Cardiff Oncology (CRDF)

• Market cap: $249M
• 1 day: -0.27%
• 5 days: -5.54%
• 1 month: -21.05%
• 3 months: -7.86%
• 6 months: 45.35%
• Year to date: -11.97%
• 1 year: -27.04%
• 5 years: 362.96%
• 10 years: -99.27%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Employees: 33

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1,133% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 3

257% more capital invested

Capital invested by funds: $34.1M [Q3] → $122M (+$87.7M) [Q4]

253% more call options, than puts

Call options by funds: $4.64M | Put options by funds: $1.32M

124% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 17

40% more funds holding

Funds holding: 83 [Q3] → 116 (+33) [Q4]

14.75% more ownership

Funds ownership: 27.45% [Q3] → 42.2% (+14.75%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $17 353% upside
• Avg. target: $17 353% upside
• High target: $17 353% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Robert Burns 23% 1-year accuracy 39 / 168 met price target

353% upside $17

Buy Maintained

28 Feb 2025